WINT - Historical Earnings Price Analysis

Stock Information for Windtree Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Windtree Therapeutics Inc.

Windtree Announces Publication of Istaroxime Positive Phase 2 SEISMiC B Study
Windtree Receives Offer for Its Preclinical Oncology Drug Candidate
Windtree Announces Transformational Agreement to Acquire Revenue Generating Environmental Services Business
Windtree Announces Plan for Cryptocurrency Treasury Policy
Windtree Therapeutics Announces Istaroxime Cardiogenic Shock SCAI Stage C Phase 2 Study Planned Interim Analysis Results Targeted for July 2025
Windtree Therapeutics Announces Istaroxime Presentation at European Society of Cardiology Heart Failure Conference
Windtree Therapeutics Reports First Quarter 2025 Financial Results and Provides Key Business Updates
Windtree Therapeutics Announces Presentation of Preclinical Data on Istaroxime and a Selective SERCA2a Activator at the European Society of Cardiology Heart Failure Conference May 17, 2025

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.